Antibody-drug conjugates (ADCs) 定制
抗體藥物結(jié)合物（ADC）定制
are new-generation anti-cancer immunotherapeutic agents that accurately deliver cytotoxic agents to cancer cells to achieve caner elimination without damaging normal tissues. ADCs carry extremely high potent toxins and their pharmacokinetic properties and safety profile need to be extensively evaluated before deploying to human clinical trials. One crucial aspect in ADC pharmacokinetic (PK) property is the ratio of total and conjugated antibody after certain time period of deployment. This is usually assayed using immuno-colorimetric assay methods such as ELISA. To detect and quantify conjugated antibody, an agent that targets the drug portion of the ADC is desired.
是新一代抗癌免疫治療劑，能夠準(zhǔn)確地將細(xì)胞毒性藥物輸送到癌細(xì)胞，從而在不損害正常組織的情況下消除癌癥。ADC攜帶極強(qiáng)的毒素，在用于人體臨床試驗(yàn)之前，需要對(duì)其藥代動(dòng)力學(xué)特性和安全性進(jìn)行廣泛評(píng)估。ADC藥代動(dòng)力學(xué)（PK）特性的一個(gè)關(guān)鍵方面是在一定時(shí)間部署后總抗體和結(jié)合抗體的比率。通常使用免疫比色分析法（如ELISA）進(jìn)行檢測(cè)。為了檢測(cè)和量化結(jié)合抗體，需要一種針對(duì)ADC藥物部分的試劑。
Due to the high potency of ADC toxins, antibodies against these chemical compounds are difficult to develop. Only low dosages of a toxin can be applied for animal immunization and the corresponding immune response is low in small rodents. After devoting a tremendous amount of effort, Creative Biolabs has raised a series of antibodies, collectively anti-drug Abs, against ADC toxin antigens include MMAE, MMAF, DM1, DM4, Calicheamicin, Duocarmycin…. These anti-drug Abs will be valuable assets to facilitate the PK and safety evaluation of newly developed ADCs bearing these drugs.
由于ADC毒素的高效價(jià)，很難產(chǎn)生針對(duì)這些化合物的抗體。只有低劑量的毒素才能用于動(dòng)物免疫，而小嚙齒類動(dòng)物的相應(yīng)免疫反應(yīng)較低。經(jīng)過(guò)大量努力，Creative Biolabs已經(jīng)研發(fā)出一系列抗體，統(tǒng)稱為抗藥物抗體，針對(duì)ADC毒素抗原，包括MMAE、MMAF、DM1、DM4、卡利霉素、杜卡霉素…。這些抗藥物抗體將是有價(jià)值的資產(chǎn)，有助于對(duì)攜帶這些藥物的新開(kāi)發(fā)ADC進(jìn)行PK和安全性評(píng)估。
